Open Access
ARTICLE
Sheng Li*1, Guoren Zhou*1, Wei Liu†, Jinjun Ye†, Fangliang Yuan‡, Zhi Zhang‡
Oncology Research, Vol.28, No.7-8, pp. 685-700, 2020, DOI:10.3727/096504020X15917007265498
Abstract Curcumol (Cur), isolated from the Traditional Chinese Medical plant Rhizoma Curcumae, is the bioactive
component of sesquiterpene reported to possess antitumor activity. However, its bioactivity and mechanisms
against lung adenocarcinoma are still unclear. We investigated its effect on lung adenocarcinoma and elucidated its underlying molecular mechanisms. In vitro, Cur effectively suppressed proliferation, migration, and
invasion of lung adenocarcinoma cells A549 and H460, which were associated with the altered expressions of
signaling molecules, including p-AKT, p-PI3K, p-LRP5/6, AXIN, APC, GSK3 and p- -catenin, matrix metalloproteinase (MMP)-2, and MMP-9. Furthermore, Cur significantly induced cell apoptosis of A549 and H460
by promoting the… More >
Open Access
ARTICLE
Ching-Wen Huang*, Cheng-Jen Ma*†, Wei-Chih Su*, Yi-Ting Chen‡§, Hsiang-Lin Tsai*¶, Yung-Sung Yeh*#,
Tsung-Kun Chang*, Wen-Hung Hsu**††, Fang-Jung Yu**††, Jaw-Yuan Wang*¶‡‡§§¶¶##
Oncology Research, Vol.28, No.7-8, pp. 701-714, 2020, DOI:10.3727/096504020X15986099915822
Abstract This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in
patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression.
We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant
chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy with oral capecitabine (daily dose of 850 mg/m2
, twice daily, on days 1–14 every 3 weeks for 6 months) on survival according to
treatment group and EGFR expression were analyzed. By conducting an in vitro cell line study and in vivo study
through… More >
Open Access
ARTICLE
Pihua Han*†1, Haiming Yang‡1, Xiang Li*1, Jie Wu*, Peili Wang§, Dapeng Liu*, Guodong Xiao¶, Xin Sun*, Hong Ren*
Oncology Research, Vol.28, No.7-8, pp. 715-729, 2020, DOI:10.3727/096504020X16037124605559
Abstract The aim of this study was to identify a novel cancer stemness-related ceRNA regulatory axis in lung adenocarcinoma (LUAD) via weighted gene coexpression network analysis of a stemness index. The RNA sequencing
expression profiles of 513 cancer samples and 60 normal samples were obtained from the TCGA database.
Differentially expressed mRNAs (DEmRNAs), lncRNAs (DElncRNAs), and miRNAs (DEmiRNAs) were
identified with R software. Functional enrichment analysis was conducted using DAVID 6.8. The ceRNA
network was constructed via multiple bioinformatics analyses, and the correlations between possible ceRNAs
and prognosis were analyzed using Kaplan–Meier plots. WGCNA was then applied to distinguish key genes… More >
Open Access
ARTICLE
Huiling Wang*, Xin Hu†, Feng Yang‡, Hui Xiao*
Oncology Research, Vol.28, No.7-8, pp. 731-744, 2020, DOI:10.3727/096504020X16100888208039
Abstract This study was designed to investigate the precise mechanisms of miR-325-3p/S100A2 axis in breast cancer
(BC). In this study, we found that the level of miR-325-3p was dramatically increased in BC tissues and cell
lines, and the expression of S100A2 was significantly decreased. Also, the high level of miR-325-3p was
closely associated with low expression of S100A2 in BC tissues. Moreover, introduction of miR-325-3p significantly promoted proliferation, invasion, and EMT of BC cells. Bioinformatics analysis predicted that the
S100A2 was a potential target gene of miR-325-3p. Luciferase reporter assay demonstrated that miR-325-3p
could directly target S100A2. In addition, miR-325-3p overexpression… More >
Open Access
ARTICLE
Huan Ma1, Cong Nie1, Ying Chen, Jinmiao Li, Yanjie Xie, Zhixin Tang, Yang Gao, Siming Ai,
Yuxiang Mao, Qian Sun, Rong Lu
Oncology Research, Vol.28, No.7-8, pp. 745-761, 2020, DOI:10.3727/096504021X16130322409507
Abstract Cell cycle deregulation is involved in the pathogenesis of many cancers and is often associated with protein
kinase aberrations, including the polo-like kinase 1 (PLK1). We used retinoblastoma, an intraocular malignancy that lacks targeted therapy, as a disease model and set out to reveal targetability of PLK1 with a small
molecular inhibitor ON-01910.Na. First, transcriptomic analysis on patient retinoblastoma tissues suggested
that cell cycle progression was deregulated and confirmed that PLK1 pathway was upregulated. Next, antitumor activity of ON-01910.Na was investigated in both cellular and animal levels. Cytotoxicity induced by
ON-01910.Na was tumor specific and dose dependent in retinoblastoma cells,… More >
Open Access
ARTICLE
Hongde Li*†‡, Yueshuo Li*†‡, Jianmin Hu*†‡, Sufang Liu§, Xiangjian Luo*†‡¶, Min Tang*†‡,
Ann M. Bode#, Zigang Dong#**, Xinqi Liu††, Weihua Liao‡‡, Ya Cao*†‡¶ §§¶¶
Oncology Research, Vol.28, No.7-8, pp. 763-778, 2020, DOI:10.3727/096504021X16135618512563
Abstract Epstein–Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) plays an important oncogenic role in
the viral latent infection. Recently, increasing evidence indicates that the high expression of LMP1 during EBV
lytic cycle is related to the viral lytic replication. However, the mechanism by which LMP1 regulates EBV
lytic replication remains unclear. (−)-Epigallocatechin-3-gallate (EGCG) prevents carcinogenesis by directly
targeting numerous membrane proteins and effectively inhibits EBV lytic cascade. Here, we demonstrated that
LMP1 promotes EBV lytic replication through the downstream signal molecules MAPKs, including ERKs,
p38, and JNKs. LMP1 induces the phosphorylation of p53 through MAPKs to enhance the ability of… More >
Open Access
ARTICLE
Sarah A. Scuderi*, Marika Lanza*, Giovanna Casili*, Francesca Esposito†, Cristina Colarossi‡, Dario Giuffrida‡, Paterniti Irene*, Salvatore Cuzzocrea*,* Emanuela Esposito*, Michela Campolo*
Oncology Research, Vol.28, No.7-8, pp. 779-790, 2020, DOI:10.3727/096504021X16161478258040
Abstract Glioma are common malignant brain tumors, among which glioblastoma multiforme (GBM) has the worst
prognosis. Different studies of GBM revealed that targeting nuclear factor B (NF- B) induced an attenuation
tumor proliferation and prolonged cell survival. TBK1 {TANK [TRAF (TNF (tumor-necrosis-factor) receptorassociated factor)-associated NF- B activator]-binding kinase 1} is a serine/threonine protein kinase, and it is
a member of the I B kinase (IKK) family involved in NF- B pathway activation. The aim of this study was
to investigate the potential effect of BX795, an inhibitor of TBK1, in an in vitro and ex vivo model of GBM.
GBM cell… More >
Open Access
ARTICLE
Chunmou Li*1, Xiaomin Peng*1, Chuchu Feng*1, Xilin Xiong*, Jianxin Li†, Ning Liao‡, Zhen Yang§, Aiguo Liu¶, Pingping Wu*, Xuehong Liang†, Yunyan He‡, Xin Tian§, Yunbi Lin§, Songmi Wang¶, Yang Li*
Oncology Research, Vol.28, No.7-8, pp. 791-800, 2020, DOI:10.3727/096504021X16184815905096
Abstract This nonrandomized, multicenter cohort, open-label clinical trial evaluated the efficacy and safety of combined
chemotherapy with arsenic trioxide (ATO) in children with stage 4/M neuroblastoma (NB). We enrolled patients
who were newly diagnosed with NB and assessed as stage 4/M and received either traditional chemotherapy
or ATO combined with chemotherapy according to their own wishes. Twenty-two patients were enrolled in
the trial group (ATO combined with chemotherapy), and 13 patients were enrolled in the control group (traditional chemotherapy). Objective response rate (ORR) at 4 weeks after completing induction chemotherapy was
defined as the main outcome, and adverse events were monitored… More >
Open Access
ARTICLE
Tsung-Kun Chang*†, Tzu-Chieh Yin‡§, Wei-Chih Su*†, Hsiang-Lin Tsai*¶, Ching-Wen Huang*¶, Yen-Cheng Chen*, Ching-Chun Li*, Po-Jung Chen*, Cheng-Jen Ma*§, Kuo-Hsiang Chuang#, Tian-Lu Cheng**, Jaw-Yuan Wang*†¶††‡‡§§
Oncology Research, Vol.28, No.7-8, pp. 801-809, 2020, DOI:10.3727/096504021X16218531628569
Abstract Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer
(mCRC) patients. Diarrhea is the most common adverse event (AE). The underlying mechanism of irinotecaninduced diarrhea is intestinal mucosal damage caused by SN-38 (active metabolite of irinotecan) hydrolyzed
from SN-38G (inactive metabolite) by bacterial -glucuronidase ( G). According to an animal study, silymarin
reduces the activity of bacterial G without impairing antitumor efficacy. We conducted a prospective openlabel pilot study to evaluate the effect of silymarin as supplementation in reducing toxicities of mCRC patients
undergoing irinotecan-based chemotherapy. We enrolled and randomized 70 mCRC patients receiving first-line… More >
Open Access
BRIEF COMMUNICATION
Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis
Oncology Research, Vol.28, No.7-8, pp. 811-814, 2020, DOI:10.3727/096504020X15965357399750
Abstract Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute
myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our
institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with
late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At
relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML
relapse, seven patients received induction chemotherapy and two patients received hypomethylating agents
with… More >
Open Access
ERRATUM
Weichen Hou*, Lei Song†, Yang Zhao*, Qun Liu*, Shuyan Zhang‡
Oncology Research, Vol.28, No.7-8, pp. 815-818, 2020, DOI:10.3727/096504021X16240202939988
Abstract The role of miRNAs in the radiosensitivity of glioma cells and the underlying mechanism is still far from
clear. In the present study, we detected six downregulated and seven upregulated miRNAs in the serum after
radiotherapy compared with paired serum samples before radiotherapy via miRNA panel PCR. Among these,
miR-17-5p was highly reduced (fold change = −4.21). Further, we validated the levels of miR-17-5p in all
serum samples with qRT-PCR. In addition, statistical analysis suggested that a reduced miR-17-5P level was
positively associated with advanced clinical stage of glioma, incidence of relapse, and tumor differentiation.
Moreover, we provided evidence that… More >
Open Access
ERRATUM
Chang Li*, Xiaoping Li†, Shuohui Gao*, Chang Li‡, Lianjun Ma§
Oncology Research, Vol.28, No.7-8, pp. 819-822, 2020, DOI:10.3727/096504021X16240202940003
Abstract Gastric cancer is the fourth most common type of cancer and the second highest leading cause of cancer-related
deaths worldwide. It has already been established that miR-133a is involved in gastric cancer. In this study, we
investigated the molecular mechanisms by which miR-133a inhibits the proliferation of gastric cancer cells.
We analyzed the proliferative capacity of human gastric cancer cells SNU-1 using an MTT assay. Cell apoptosis was determined using flow cytometry. The expression levels of ERBB2, p-ERK1/2, and p-AKT in SNU-1
cells were determined using Western blot analysis. To confirm that ERBB2 is a direct target of miR-133a, a… More >
Open Access
ERRATUM
Yanli Wang*, Jia Li†, Chunling Xu†, Xiaomeng Zhang†
Oncology Research, Vol.28, No.7-8, pp. 823-825, 2020, DOI:10.3727/096504021X16240202940021
Abstract Increasing evidence indicates that the dysregulation of microRNAs is associated with the development and
progression of various cancers. MicroRNA-139-5p (miR-139-5p) has been reported to have a tumor suppressive role in many types of cancers. The role of miR-139-5p in ovarian cancer (OC) is poorly understood. The
purpose of the present study was to explore the expression of miR-139-5p and its function in OC. The results
showed that miR-139-5p expression was markedly downregulated in OC tissues and cell lines. In addition,
underexpression of miR-139-5p was significantly associated with FIGO stage, lymph mode metastasis, and
poor overall survival of OC patients. Functional… More >
Open Access
ERRATUM
Dong Li*1, Fei-fan Sun*1, Dan Wang*1,Tao Wang*, Jing-jing Peng*, Jian-Qiong Feng*, Hua Li*, Chao Wang†, Dai-jun Zhou*, Hong Luo*, Zeng-qiang Fu*, Tao Zhang*
Oncology Research, Vol.28, No.7-8, pp. 827-828, 2020, DOI:10.3727/096504021X16280937554409
Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma
(HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1
(PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it
has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However,
the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this
study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated
PD-L1 depletion attenuated drug resistance and suppressed the migration,… More >
Open Access
RETRACTION
Wenliang Liu*, Peng Xiao†, Han Wu*, Li Wang*, Demiao Kong*, Fenglei Yu*
Oncology Research, Vol.28, No.7-8, pp. 829-829, 2020, DOI:10.3727/096504021X16207253542097
Abstract This article has no abstract. More >
Open Access
RETRACTION
Zhili Cao*1, Xiang Zheng†1, Lei Cao*, Naixin Liang*
Oncology Research, Vol.28, No.7-8, pp. 831-831, 2020, DOI:10.3727/096504020X16231418632584
Abstract This article has no abstract. More >
Open Access
RETRACTION
Chao Jiang*, Xueyan Liu†, Meng Wang*, Guoyue Lv*, Guangyi Wang*
Oncology Research, Vol.28, No.7-8, pp. 833-833, 2020, DOI:10.3727/096504018X16233193839045
Abstract This article has no abstract. More >
Open Access
RETRACTION
Lili Lv*, Xiaodong Wang†
Oncology Research, Vol.28, No.7-8, pp. 835-835, 2020
Abstract This article has no abstract. More >
Login
Register
Submit a Paper
Propose a Special lssue